AM in the time of COVID-19AM IndustryDistribution

Stratasys will support Origin by delivering millions of 3D printed nasopharyngeal swabs

Reaching healthcare providers by leveraging its established distribution channels

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

In response to the pressing need for more COVID-19 testing, Stratasys, Inc. and high-speed layerless stereolithography 3D printer manufacturer Origin have signed an agreement in which Stratasys will market and promote Origin 3D printed nasopharyngeal swabs to healthcare providers and other testing centers in the U.S.

As widely reported, widespread testing of millions of people is currently hampered by a shortage of testing supplies. High-speed stereolithography 3D printers such as those from Carbon but also low-cost ones from Formlabs have proven capable of mass-producing nasal swabs (as have some laser sintering systems). Each Origin One 3D printer has shown it has the ability to produce batches of 1,500 Origin NP O1 Swabs at a time, multiple times daily. Origin is moving towards a streamlined process allowing the production of approximately 190,000 per day, or 1.3 million per week.

Stratasys will leverage its position as a leading provider of 3D printing solutions to the healthcare industry to market Origin NP O1 Swabs. Stratasys has already been actively serving healthcare systems across the country during the pandemic by leading a coalition that has been providing 3D-printed face shields to nearly 100 front-line organizations. To date, the coalition has provided about 40,000 shields at no cost to health systems.

3D printed nasopharyngeal swabs

“We have tremendous confidence in Origin’s 3D printing technology, and we’re confident in our ability to help bring them to market efficiently,” said Stratasys Americas President Rich Garrity adding that Stratasys is ready to help get millions of swabs to wherever they are most needed.

“We believe widespread testing can help save lives and get our economy going again, and we’re confident that our Origin One technology and simple material requirements will be able to produce millions of swabs to meet the need,” said Origin CEO, Christopher Prucha “We’ve been impressed by the speed with which Stratasys has been able to provide thousands of shields to healthcare systems across the country and believe they are the right partner for helping get millions of swabs where they are most needed.”

Origin swabs were tested in a clinical trial with Beth Israel Deaconess Medical Center, an academic medical center affiliated with Harvard Medical School. Origin reports that results show  Origin swabs performed the highest with regard to concordance to control swabs compared to two other 3D printed swabs. In addition, in subjective feedback, Origin swabs were preferred over the other 3D printed swabs.

Each Origin NP O1 Swab is autoclavable and individually packaged.

Consumer Products AM 2024

1,346 polymer and metal AM companies and 143 end-users. Consumer products AM generated $2.6 billion in 2023. Segment expected to grow to $28 billion by 2033 at 26.8% CAGR. This new market study fro...

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.